OPKO Health reports that institutional investors hold 64.6% of its outstanding shares, while insiders — including executive officers and board members — control 49.7%. Such concentrated ownership by funds, endowments and company insiders suggests strong confidence in OPKO’s long-term prospects and alignment between management and large shareholders.

The company’s stock carries a beta of 1.39, indicating that it has historically been 39% more volatile than the S&P 500. This higher sensitivity to market swings reflects OPKO’s small-cap status and exposure to both diagnostic testing and novel pharmaceutical development, sectors that can react sharply to regulatory and clinical data news.

For its most recent fiscal year, OPKO Health generated $713.1 million in revenue but recorded a net loss of $53.22 million, translating to an EPS of negative $0.25. The shares trade at a price-to-sales ratio of 1.38, while the trailing price-to-earnings ratio stands at negative 5.12, underscoring investor caution given the ongoing unprofitability.

Market consensus compiled by analysts yields a rating score of 2.43, based on one sell, three hold, two buy and one strong-buy recommendation. The average price target is $2.28, implying upside potential of approximately 78% from current levels. This bullish tilt reflects expectations for improved margins at BioReference Laboratories and progress in OPKO’s pipeline assets.